Clinical trials
catalyst calendar across sponsors →Studies where STTK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 5 with posted results
Held by 6 tracked-famous managers (Point72 Asset Management, L.P., RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, Squarepoint Ops LLC, +1 more) · FINRA short interest 5.3 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of SL-325 in Crohn's Disease PatientsNCT07753850Proportion of participants who achieve endoscopic responseRandomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: SL-325, Placebo | Crohn's Disease | 232 | Jul 2028 | ≤ 712 d | 2026-08-12 |
| Phase 1 Study of SL-325 in Healthy VolunteersNCT07158437Safety and TolerabilityRandomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Biological: SL-325 · Other: Placebo (Normal Saline) | Healthy Volunteers | 72 | Jul 2026 | — | 2026-04-30 |
| Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersNCT05483933results2025-12-23Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or MirvetixumabNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 86 | 2025-02-07actual | — | 2025-12-23 |
| Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLNCT05275439results2026-03-18Safety Profile of SL-172154 Monotherapy or in Combination With AzacitidineNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Development discontinued | Drug: SL-172154, Azacitidine (AZA), Venetoclax | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 106 | 2025-02-06actual | — | 2026-03-18 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or LymphomasNCT03894618results2025-03-14Safety Profile of SL-279252Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: SL-279252 | Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2023-05-04actual | — | 2025-04-02 |
| Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerNCT04406623results2025-01-30Safety Profile of SL-172154Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: SL-172154 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 27 | 2023-02-02actual | — | 2025-01-30 |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or SkinNCT04502888results2025-02-24Incidence of All Treatment Emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: Drug: SL-172154 | Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck | 5 | 2022-04-08actual | — | 2025-02-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19